Open Access15-Deoxy-Δ12,14 Prostaglandin J2 Reduces the Formation of Atherosclerotic Lesions in Apolipoprotein E Knockout Mice
Author(s) -
Taiko Seno,
Masahide Hamaguchi,
Eishi Ashihara,
Masataka Kohno,
H. Ishino,
Aihiro Yamamoto,
Masumi Kadoya,
Kaoru Nakamura,
Ken Murakami,
Satoaki Matoba,
Taira Maekawa,
Yutaka Kawahito
Publication year - 2011
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0025541
Subject(s) - lesion , apolipoprotein e , immunohistochemistry , apolipoprotein b , knockout mouse , medicine , receptor , inflammation , endocrinology , peroxisome proliferator activated receptor , in vivo , agonist , prostaglandin , biology , pathology , cholesterol , microbiology and biotechnology , disease
Aim 15-Deoxy-Δ 12,14 Prostaglandin J 2 (15d-PGJ 2 ) is a ligand of peroxisome proliferator-activated receptor γ (PPARγ) having diverse effects such as the differentiation of adipocytes and atherosclerotic lesion formation. 15d-PGJ 2 can also regulate the expression of inflammatory mediators on immune cells independent of PPARγ. We investigated the antiatherogenic effect of 15d-PGJ 2 . Methods We fed apolipoprotein (apo) E-deficient female mice a Western-type diet from 8 to 16 wk of age and administered 1 mg/kg/day 15d-PGJ 2 intraperitoneally. We measured atherosclerotic lesions at the aortic root, and examined the expression of macrophage and inflammatory atherosclerotic molecules by immunohistochemical and real-time PCR in the lesion. Results Atherosclerotic lesion formation was reduced in apo E-null mice treated with 15d-PGJ 2 , as compared to in the controls. Immunohistochemical and real-time PCR analyses showed that the expression of MCP-1, TNF-α, and MMP-9 in atherosclerotic lesions was significantly decreased in 15d-PGJ 2 treated mice. The 15d-PGJ 2 also reduced the expression of macrophages and RelA mRNA in atherosclerotic lesions. Conclusion This is the first report 15d-PGJ 2 , a natural PPARγ agonist, can improve atherosclerotic lesions in vivo. 15d-PGJ 2 may be a beneficial therapeutic agent for atherosclerosis.